<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644395</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-2012-417</org_study_id>
    <nct_id>NCT02644395</nct_id>
  </id_info>
  <brief_title>Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus</brief_title>
  <acronym>TT</acronym>
  <official_title>Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Calcineurin inhibitors (CNIs) are the most commonly used immunosuppressive drugs
      to prevent rejection after kidney transplantation. However, the efficacy of preventing
      rejection comes at the cost of important side-effects. Among the most common side-effects is
      hypertension. Hypertension after kidney transplantation is clinically relevant, because it
      increases the risk of cardiovascular disease and is associated with increased graft loss and
      recipient mortality. The mechanism of CNI-induced hypertension is incompletely understood
      and, therefore, the treatment is currently empiric. These and other investigators recently
      showed that CNIs cause salt-sensitive hypertension by activating a sodium transporter in the
      kidney, namely the thiazide-sensitive sodium chloride cotransporter.

      Hypothesis: The investigators hypothesize that thiazide diuretics are non-inferior to calcium
      channel blockers (CCBs) (currently usually the treatment of choice) for the treatment of
      CNI-induced hypertension.

      Objective: To compare the blood pressure response to thiazide diuretics and CCBs in patients
      with CNI-induced hypertension.

      Study design: Single-center, randomized cross-over trial.

      Study population: Kidney transplant recipients with a good functioning allograft (eGFR &gt; 30
      ml/min) who are hypertensive (daytime systolic blood pressure &gt; 140 mm Hg) and who do not
      have proteinuria (&lt; 1 g/day).

      Intervention: Patients will be randomized to receive chlorthalidone (12.5 mg once daily, if
      needed titrated to 25 mg once daily) or amlodipine (5 mg once daily, if needed titrated to 10
      mg once daily).

      Main study parameters/endpoints: 24-hour blood pressure recording.

      Nature and extent of the burden and risks associated with participation, benefit and group
      relatedness: Both drugs have long been registered for the treatment of hypertension. The
      side-effect profile of both drugs is considered to be equal. The burden of the study for the
      patients are blood pressure measurements using 30-minute automated blood pressure measurement
      and 24-hour ambulatory blood pressure measurement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 18, 2013</start_date>
  <completion_date type="Actual">December 19, 2016</completion_date>
  <primary_completion_date type="Actual">December 17, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average daytime SBP</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Hypertension</condition>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Amlodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Current treatment of choice</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorthalidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testing new indication for approved drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorthalidone</intervention_name>
    <description>Drug</description>
    <arm_group_label>Chlorthalidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Drug</description>
    <arm_group_label>Amlodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Kidney transplant recipients using tacrolimus

          -  Average daytime SBP &gt; 140 mm Hg (ABPM)

          -  eGFR &gt; 30 ml/min (MDRD)

        Exclusion Criteria:

          -  Use of glucocorticoids, co-trimoxazole, diuretics

          -  Pregnancy

          -  Serum sodium &lt; 136, serum potassium &lt; 3.5

          -  Proteinuria &gt; 1 g/day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ErasmusMC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Moes AD, Hesselink DA, van den Meiracker AH, Zietse R, Hoorn EJ. Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. Am J Kidney Dis. 2017 Jun;69(6):796-804. doi: 10.1053/j.ajkd.2016.12.017. Epub 2017 Mar 1.</citation>
    <PMID>28259499</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2015</study_first_submitted>
  <study_first_submitted_qc>December 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>June 15, 2017</last_update_submitted>
  <last_update_submitted_qc>June 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Ewout Hoorn</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Chlorthalidone</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

